低剂量乙胺对剖腹产产后母亲抑郁症的影响
Yan Shang1, Siyuan Li2, Qin Zheng3
1Anesthesia & Surgery Center, Xi'an Daxing Hospital, Xi'an, Shaanxi, China.
Journal of psychosomatic obstetrics and gynaecology
|July 3, 2025
概括
低剂量静脉注射的埃斯凯坦胺在剖腹产后的妇女中显著降低了产后抑郁症得分. 这种治疗显示出安全的特征,尽管与患者控制的静脉静脉止痛相结合时,轻微的不良事件更为频繁.
科学领域:
- 麻醉学 麻醉学
- 产科 产科 产科 产科 产科
- 精神病学是一个精神病学.
背景情况:
- 产后抑郁症 (PPD) 是影响分娩后妇女的一个重大问题.
- 剖腹产是常见的外科手术,与PPD风险增加有关.
- 有效的干预措施,以减轻PPD在这个人群中至关重要.
研究的目的:
- 评估低剂量静脉注射乙胺在降低PPD得分方面的有效性.
- 评估胺对睡眠质量和剖腹产后疼痛的影响.
- 为了确定在分娩后期使用埃斯基坦胺的安全性.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及186名接受剖腹产的妇女.
- 参与者接受了手术内和/或患者控制的静脉注射止痛药 (PCIA) 或安慰剂.
- 主要结局是爱丁堡产后抑郁症评分 (EPDS) 的变化;次要结局包括睡眠质量,疼痛和不良事件.
主要成果:
- 这两组在产后5,7天和14天,与安慰剂相比,ESKETAMINE的EPDS得分显著降低,与安慰剂相比.
- 两组之间在睡眠质量 (PSQI),疼痛 (VAS) 或PCIA使用方面没有发现显著差异.
- 轻度,短暂的不良事件在接受ESKETAMINE在手术内和通过PCIA的组中更为频繁.
结论:
- 低剂量静脉注射的埃斯凯坦胺有效降低了剖腹产后妇女的产后抑郁症得分.
- 在这种情况下,石胺似乎具有安全的特征,并具有可管理的不良事件.
- 进一步的研究可能会探索优化esketamine疗程以平衡疗效和副作用.
相关概念视频
Electroconvulsive Therapy
200
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
200
Parenteral Anesthetics: Overview
203
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
203
Antidepressant Drugs: MAOIs and Other Agents
373
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
373


